MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Files An 8-K Other Events
Item 8.01
Provisional Patent Filing
On August 18, 2020 Oncotelic, Inc. (“Oncotelic”), a wholly-owned subsidiary of Mateon Therapeutics, Inc. (“Mateon” or the “Company”), filed a provisional patent application on the method of use and composition of matter for second generation COVID-19 vaccine leveraging on OT-101 as adjuvant. To avoid the two potential issues wiith 1st generation vaccine against COVID-19, we will be combining the 1st generation COVID-19 DNA vaccine with a TGF-β inhibitor (OT-101) to stimulate a strong immune response while suppressing the IgA class switching that could aggravate the disease through Kawasaki reaction- IgA vasculitis. The company is aggressively pursuing the development of this 2nd generation COVID-19 vaccine expecting that the 1st generation vaccines would not be fully effective and may not be sufficient to counter the current pandemic.
Press releases
The provisional filing build on continual development of OT-101 as therapeutic against COVID-19. As related by the press releases over the past few months, OT-101 development as COVID-19 therapeutic is continuing.
June 23, 2020 (GLOBE NEWSWIRE) – Mateon Therapeutics selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.
June 24, 2020 (GLOBE NEWSWIRE) — Oncotelic Inc. announced that IBM has granted access to its IBM Clinical Development (ICD) platform free of charge for the clinical trial evaluating the potential of Mateon’s lead drug candidate OT-101 in COVID-19 patients. The award was made following IBM’s review of the program and is designed to help accelerate the upcoming phase II COVID-19 clinical trial.
June 29, 2020 (GLOBE NEWSWIRE) – Mateon Therapeutics, Inc. announced it has secured a $2 million in debt financing with Golden Mountain Partners (GMP) for the conduct of a clinical trial evaluating OT-101 against COVID-19. This is a 1-year convertible note with 2% annual interest, personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of Mateon. The note is convertible at the 1 year anniversary of the note, at the common stock price of the Company on conversion with no discount. GMP does not have the option to convert prior to the 1-year anniversary.
July 7, 2020 (GLOBE NEWSWIRE) – Mateon Therapeutics appointed Anthony Maida, III, Ph.D., MA, MBA as Chief Clinical Officer – Translational Medicine for the Company to lead our clinical trials including our COVID-19 trials.
July 9, 2020 (GLOBE NEWSWIRE) – Mateon Therapeutics appointed Giancarlo Mennella, Managing Director at EGAMID LTD, to lead its licensing activity for Trabedersen (OT-101) for COVID-19 globally with emphasis on South America where the treatment for COVID-19 is especially needed.
(d) Exhibits.
| 99.1 | 6-23-2020- IQVIA Press Release | Filed herewith. |
| 99.2 | 6-24-2020- IBM ICD Press Release | Filed herewith. |
| 99.3 | 6-29-2020- GMP Press release | Filed herewith. |
| 99.4 | 7-7-2020- Anthony Maida Press Release | Filed herewith |
| 99.5 | 7-9-2020- Giancarlo Mennella Press Release | Filed herewith |
MATEON THERAPEUTICS INC Exhibit
EX-99.1 2 ex99-1.htm Exhibit 99.1 Mateon Therapeutics Selects IQVIA for its Randomized,…
To view the full exhibit click here
About MATEON THERAPEUTICS, INC. (OTCMKTS:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.